Over 14 years, prognosis is poor, and misdiagnosis is uncommon.
Patients with functional neurologic symptoms are a challenging and frequent presence in clinical practice. Investigators identified 107 patients with functional limb weakness who had been referred to a tertiary center specializing in this condition and tracked them for a mean follow-up of 14 years.
Among 89 with follow-up diagnostic information, 4 (4%) developed a diagnosable neurologic condition: multiple sclerosis, Huntington disease, Parkinson disease, or idiopathic cerebellar degeneration. In 65 patients with outcomes data, the functional weakness resolved in 20%, improved in 31%, and was the same or worse in 49%. Fair or poor general health was reported by 54%, and 41% were not employed for health-related reasons. Also, 51% agreed that …
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)